EPAS1 and cancer: Bruick, Gardner, MacMillan, and Tambar identify a high‐affinity binding, potent, and subtype‐selective inhibitor of HIF‐2α in cancer cells: tetrazolium tetrahydro pyrimidine (S, R), a potent inhibitor of HIF‐2α, which provides a novel, artificial pathway for targeting deregulated HIF activity and lays the groundwork for ongoing studies of in vivo antagonism of HIF‐2α in animal models of cancer [83].